Clinical trials recruiting in Chino, California

Phase breakdown

Conditions recruiting in Chino, California

Recruiting trials in Chino, California

• A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
  NCT04777357 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female)
• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
  NCT06929273 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
  NCT07755410 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
  NCT06947941 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
  NCT07621237 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
  NCT07105111 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
  NCT07140913 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
  NCT07288567 · Phase: Phase 3 · Ages: 13 Years to 17 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
  NCT07065240 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
  NCT07424404 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female)
• ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
  NCT07284667 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• ALTO-207 in Adults With Treatment-resistant Depression (TRD)
  NCT07553637 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
  NCT07484217 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
  NCT06052254 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female)
• Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
  NCT07379827 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06963021 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
  NCT07114874 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
  NCT05980949 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
  NCT07686263 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
  NCT06808984 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Chino, California?

21 recruiting trials have at least one study site in Chino, California.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.